<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00642369</url>
  </required_header>
  <id_info>
    <org_study_id>D1443L00053</org_study_id>
    <nct_id>NCT00642369</nct_id>
  </id_info>
  <brief_title>A 4-week, Randomized, Rater-blinded, Parallel Study to Evaluate Quetiapine in Improving Sleep Quality of Schizophrenia</brief_title>
  <official_title>Study of Evaluating Quetiapine in Improving Sleep Quality of Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guang Dong Provincial Mental Health Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guang Dong Provincial Mental Health Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will apply polysomnography (PSG) to evaluate the effect of quetiapine fumarate on
      sleep architecture. Most of previous studies evaluated sleep by self-reported questionnaires
      during the antipsychotic treatment (clozapine, risperidone, olanzapine, et al), while only a
      few studies with PSG evaluation had some limitation, such as: small sample size, respective
      or cross-sectional, potential sleep disorders, et al. In this study, we will investigate both
      subjective and objective effect of quetiapine fumarate in improving sleep quality in
      schizophrenic patients by PSG as well as psychiatric scales. The control drug in this study
      is the typical antipsychotic - haloperidol. It could increase sleep duration and efficiency
      by mostly increasing the S2 without effect on rapid eye movement (REM) sleep and slow wave
      sleep (SWS). The patients will be randomised into two groups as a parallel design. This study
      is designed as rater blinded to reduce the bias in evaluation. It is suggested that the
      sedative effect of quetiapine fumarate could diminish in 2 weeks, therefore, we use 4 weeks
      to ensure the change of sleep quality in this study, which could be helpful for the
      evaluation of relative short and middle term effect of quetiapine fumarate on sleep quality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. The objective sleep structures of quetiapine fumarate and haloperidol being used as
           mono-therapy respectively in the treatment of patients with acute schizophrenia are
           measured by the change of composite variables for PSG test (sleep stages, time in bed,
           total sleep time, sleep efficiency, sleep latency) from baseline to Week 4 (LOCF).

        2. The subjective sleep qualities of quetiapine fumarate and haloperidol being used as
           mono-therapy respectively in the treatment of patients with acute schizophrenia are
           measured by the change of Pittsburgh Sleep Quality Inventory (PSQI) and Epworth
           Sleepiness Scale(ESS) from baseline to Week 4 (LOCF).

        3. The clinical efficacy of quetiapine fumarate and haloperidol being used as mono-therapy
           respectively in the treatment of patients with acute schizophrenia are measured by the
           change of Positive and Negative Syndrome Scale (PANSS) and Clinical Globe Impression
           (CGI),and Calgary Depression Scale for Schizophrenia (CDSS) from baseline to Week 4
           (LOCF).

        4. The clinical safety and tolerance quetiapine fumarate and haloperidol being used as
           mono-therapy respectively in the treatment of patients with acute schizophrenia are
           measured by Treatment Emergent Symptom Scale (TESS) in day 14 and day 28.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Slow Wave Sleep</measure>
    <time_frame>28 days</time_frame>
    <description>The primary variable is the change of percentage of slow wave sleep (SWS) from baseline to the 28th day (LOCF).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Rapid Eye Movement Sleep</measure>
    <time_frame>28 days</time_frame>
    <description>The primary variable is the change of the percentage of rapid eye movement (REM)sleep from baseline to the 28th day (LOCF).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>quetiapine fumarate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>quetiapine fumarate was administered 25mg on the 1st day,738±41mg/day on the 14th day, and 738±48mg/day on the 28th day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>haloperidol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>haloperidol was administered 2mg on the 1st day,16±7mg/day on the 14th day, and 18±6mg/day on the 28th day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>quetiapine fumarate</intervention_name>
    <description>600-750mg/day</description>
    <arm_group_label>quetiapine fumarate</arm_group_label>
    <other_name>seroquel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>haloperidol</intervention_name>
    <description>6-40mg/day</description>
    <arm_group_label>haloperidol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For inclusion in the study patients must fulfill all of the following criteria:

          1. Provision of written informed consent by patient or his/her legal guardian

          2. Hospitalized for a diagnosis of Schizophrenia paranoid subtype by Diagnostic and
             Statistical Manual of Mental Disorders- Fourth Edition (DSM-IV)

          3. Positive and Negative Syndrome Scale (PANSS) total score≥60

          4. Female patients of childbearing potential must be using a reliable method of
             contraception and have a negative urine human chronic gonadotropin (HCG) test at
             enrolment

          5. Able to understand and comply with the requirements of the study

        Exclusion Criteria:

        Any of the following is regarded as a criterion for exclusion from the study:

          1. Pregnancy or lactation

          2. Any DSM-IV Axis I disorder not defined in the inclusion criteria

          3. Patients who, in the opinion of the investigator, pose an imminent risk of suicide or
             a danger to self or others

          4. Known intolerance or lack of response to quetiapine fumarate or/and haloperidol, as
             judged by the investigator

          5. Use of any of the following cytochrome P450 3A4 inhibitors in the 14 days preceding
             enrolment including but not limited to: ketoconazole, itraconazole, fluconazole,
             erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir,
             fluvoxamine and saquinavir

          6. Use of any of the following cytochrome P450 3A4 inducers in the 14 days preceding
             enrolment including but not limited to: phenytoin, carbamazepine, barbiturates,
             rifampin, St. John's Wort, and glucocorticoids

          7. Administration of a depot antipsychotic injection within one dosing interval (for the
             depot) before randomisation

          8. Substance or alcohol dependence at enrolment (except dependence in full remission, and
             except for caffeine or nicotine dependence), as defined by DSM-IV criteria

          9. Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM-IV
             criteria within 4 weeks prior to enrolment

         10. Medical conditions that would affect absorption, distribution, metabolism, or
             excretion of study treatment

         11. Unstable or inadequately treated medical illness (e.g. congestive heart failure,
             angina pectoris, hypertension) as judged by the investigator

         12. Organic changes was founded by brain CT

         13. Involvement in the planning and conduct of the study

         14. Previous enrolment or randomisation of treatment in the present study.

         15. Participation in another drug trial within 4 weeks prior enrolment into this study or
             longer in accordance with local requirements

         16. A patient with Diabetes Mellitus (DM) fulfilling one of the following criteria:
             unstable DM defined as enrolment glycosylated hemoglobin (HbA1c) &gt;8.5%; admitted to
             hospital for treatment of DM or DM related illness in past 12 weeks; not under
             physician care for DM Physician responsible for patient's DM care has not indicated
             that patient's DM is controlled; Physician responsible for patient's DM care has not
             approved patient's participation in the study; has not been on the same dose of oral
             hypoglycaemic drug(s) and/or diet for the 4 weeks prior to randomisation; for
             thiazolidinediones (glitazones) this period should not be less than 8 Weeks; taking
             insulin whose daily dose on one occasion in the past 4 weeks has been more than 10%
             above or below their mean dose in the preceding 4 weeks. Note: If a diabetic patient
             meets one of these criteria, the patient is to be excluded even if the treating
             physician believes that the patient is stable and can participate in the study.

         17. An absolute neutrophil count (ANC) of 1.5 x 109/L

         18. Sleep disorder such as Apnea Hypopneas Syndrome, periodic leg movement syndrome and
             narcolepsy

         19. The work time is rotate and/or often flies across the time zone

         20. Use of clozapine within 28 days prior to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhang Bin, Ph. D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guang Dong Provincial Mental Health Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guangdong Provincial Mental Health Institute</name>
      <address>
        <city>Guang Zhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2008</study_first_submitted>
  <study_first_submitted_qc>March 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2008</study_first_posted>
  <results_first_submitted>December 14, 2009</results_first_submitted>
  <results_first_submitted_qc>March 21, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 17, 2014</results_first_posted>
  <last_update_submitted>March 21, 2014</last_update_submitted>
  <last_update_submitted_qc>March 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guang Dong Provincial Mental Health Institute</investigator_affiliation>
    <investigator_full_name>Bin Zhang</investigator_full_name>
    <investigator_title>sleep centre</investigator_title>
  </responsible_party>
  <keyword>Polysomnograph</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Quetiapine Fumarate</title>
          <description>slow wave sleep% and rapid eye movement sleepin quetiapine fumarate treatment group</description>
        </group>
        <group group_id="P2">
          <title>Haloperidol</title>
          <description>slow wave sleep% in haloperidol treatment group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>misdiagnosis</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Quetiapine Fumarate</title>
          <description>quetiapine fumarate treatment (200-750mg/day) in 28 days</description>
        </group>
        <group group_id="B2">
          <title>Haloperidol</title>
          <description>haloperidol treatment (6-40mg/day) in 28 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.0" spread="10.1"/>
                    <measurement group_id="B2" value="27.9" spread="6.7"/>
                    <measurement group_id="B3" value="26.3" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Slow Wave Sleep</title>
        <description>The primary variable is the change of percentage of slow wave sleep (SWS) from baseline to the 28th day (LOCF).</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate</title>
            <description>percentage of slow wave sleep in quetiapine fumarate group</description>
          </group>
          <group group_id="O2">
            <title>Haloperidol</title>
            <description>percentage of slow wave sleep in haloperidol group</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Slow Wave Sleep</title>
          <description>The primary variable is the change of percentage of slow wave sleep (SWS) from baseline to the 28th day (LOCF).</description>
          <units>percentage of slow wave sleep</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>percentage at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="5.5"/>
                    <measurement group_id="O2" value="8.6" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>percentage on the 28th day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" spread="8.0"/>
                    <measurement group_id="O2" value="6.3" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>percentage change from baseline to the 28th day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="1.1"/>
                    <measurement group_id="O2" value="-2.3" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Rapid Eye Movement Sleep</title>
        <description>The primary variable is the change of the percentage of rapid eye movement (REM)sleep from baseline to the 28th day (LOCF).</description>
        <time_frame>28 days</time_frame>
        <population>For the need of the statistical analysis, the study group and the control group are 30 evaluable patients respectively. Finally, in consideration of 25% un-evaluable patients after randomisation, there should be 80 patients randomised in this study with 40 patients per arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumarate</title>
            <description>percentage of rapid eye movement sleep in quetiapine fumarate group</description>
          </group>
          <group group_id="O2">
            <title>Haloperidol</title>
            <description>percentage of rapid eye movement sleep in haloperidol group</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Rapid Eye Movement Sleep</title>
          <description>The primary variable is the change of the percentage of rapid eye movement (REM)sleep from baseline to the 28th day (LOCF).</description>
          <population>For the need of the statistical analysis, the study group and the control group are 30 evaluable patients respectively. Finally, in consideration of 25% un-evaluable patients after randomisation, there should be 80 patients randomised in this study with 40 patients per arm.</population>
          <units>percentage of rapid eye movement sleep</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>percentage at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" spread="9.1"/>
                    <measurement group_id="O2" value="13.2" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>percentage on the 28th day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" spread="9.2"/>
                    <measurement group_id="O2" value="10.4" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>percentage change from baseline to the 28th day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="3.2"/>
                    <measurement group_id="O2" value="-2.7" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Quetiapine Fumarate</title>
          <description>quetiapine fumarate treatment (200-750mg/day) in 28 days</description>
        </group>
        <group group_id="E2">
          <title>Haloperidol</title>
          <description>haloperidol treatment (6-40mg/day) in 28 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>the present study lasted for only 4 weeks. it might be too short to investigate the effect of quetiapine fumarate and haloperidol on sleep and clinical parameters.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Zhang Bin</name_or_title>
      <organization>Guang Dong Provinical Mental Health Institute</organization>
      <phone>86-20-81888553</phone>
      <email>zhang73bin@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

